Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
about
Antidepressant drug effects and depression severity: a patient-level meta-analysisSafety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathyDesvenlafaxine and weight change in major depressive disorderDesvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.Desvenlafaxine in the treatment of major depressive disorder.Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic reviewA double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorderComparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/dAntidepressant efficacy and side-effect burden: a quick guide for clinicians.Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.Evaluating the responsiveness of the Warwick Edinburgh Mental Well-Being Scale (WEMWBS): group and individual level analysisEfficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial.Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.HRT in difficult circumstances: are there any absolute contraindications?Emerging drugs for major depressive disorder.Desvenlafaxine for the treatment of major depressive disorder.The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Is the antidepressive effect of second-generation antidepressants a myth?The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.High-dose desvenlafaxine in outpatients with major depressive disorder.An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator.Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations.An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.
P2860
Q24598580-942FF552-8367-4638-8EE9-1B91A1E01CCEQ33632399-2946631C-E040-42CE-BCB1-7C35292CA276Q33824509-3A588141-017D-4883-964D-EA1435157461Q33902252-4A77AC1B-25B8-4D6F-B890-A8B1B13A1B1DQ33973909-BEEDBD38-5798-48E1-A6A5-ADCC2D2F31E1Q34163718-08522E2E-42AF-4418-93CA-A4CA967AD083Q34234091-194304E8-8DA2-4307-9ADD-5EF5474B1661Q34240696-5E5A0872-F344-4D97-9C31-78BE4393D666Q34630842-3343AA7C-4D77-40FC-A56C-EC06415C2DA0Q35162633-27095863-3880-4A46-A5FB-30D6B771BAF8Q35252115-88BA76B7-4738-4573-A9FC-CC6087E0A2E5Q36028281-766D1C70-816A-40C7-A6EA-D08E75851046Q36083244-F23CCA9B-807F-4650-B029-B4063AFF3546Q36243042-99992D1F-1A54-40C9-90F6-400D6BDD0DEEQ36332534-5C729B8B-CCE4-4618-9E0E-76DA20562BD8Q36575362-21DD749F-CAB8-4919-9511-B740E914CE16Q36606752-45D2D728-DE70-4E69-B22C-E4398760918AQ37352035-C8B09FF7-EEAF-4974-B5CB-A8DD0505D93FQ37503551-715C57DC-7C7C-45F0-B643-BA6429AB5F19Q37682552-F2CDADFE-857A-42FF-91C6-AF5E8A549888Q37808483-3179F81E-F866-4F5A-94AE-54CA7D3A711AQ37847568-E1A9308C-077D-4792-88A3-80ED2ECEA160Q37984619-CBDCC851-466F-43AD-A825-EC901E6FFA09Q38219037-35F2A5BC-3396-43AE-B687-382C31AFAFAAQ38394430-D09E9BB1-5E76-4B74-8E03-35AF453297E0Q38619996-1B973B0F-9747-48C6-8B82-268A9EBBF0D1Q38714376-24BD678E-E631-4C90-8190-F4CC7100A53DQ38817431-7D9571FB-0540-4E6A-BCF1-49D935C00938Q43674378-D9F57E74-755A-4806-95D8-D3C013842005Q45002853-D739C60E-F94A-4DFE-A597-DB1F5350B876Q46104148-95518BDF-F76F-4B47-B354-040FEF1A3829Q46377304-6269AEF6-79DC-4DD1-8A64-175D10D2FE29Q47329745-72EFD9E1-EF4F-46F2-B818-64379495F234Q47350100-478D293F-B219-485D-892C-9BF82F976694Q47593829-31ED1EA3-FD36-4C1B-82B4-B78ED8888F19Q47692217-E93B12CD-5177-4B1A-A4FE-9CA7FAABF643Q48345194-63029FF7-71E5-428F-8D18-5CA1F3F1F5AB
P2860
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@en
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@nl
type
label
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@en
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@nl
prefLabel
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@en
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@nl
P2093
P1476
Efficacy, safety, and tolerabi ...... in a placebo-controlled trial.
@en
P2093
Claudine Brisard
Jean-Michel Germain
Karen A Tourian
Patrice Boyer
Rita Ganguly
Stuart Montgomery
Sudharshan K Padmanabhan
Ulla Lepola
P304
P356
10.1097/YIC.0B013E32830CEBED
P577
2008-09-01T00:00:00Z